Why the study?
Does sildenafil 60 mg/day result in elevated maximal plasma concentrations in inpatients with left ventricular assist devices compared to the reference range?
Does sildenafil 60 mg/day result in elevated maximal plasma concentrations in inpatients with left ventricular assist devices compared to the reference range?
Inpatients with LVADs receiving sildenafil 60 mg/day frequently exhibit supratherapeutic plasma concentrations, highlighting a potential risk for concentration-related adverse events.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible supratherapeutic sildenafil exposure in LVAD patients; leaves open evidence-based dosing and safety data.
We compared maximal plasma concentrations (Cmax) of sildenafil and metabolite n-desmethyl sildenafil in 12 inpatients with left ventricular assist devices (LVADs) on sildenafil (60 mg/day) to the reference range. Sildenafil Cmax (156.8 ± 124.5 ng/ml) was elevated in 66% of patients, with a two to fivefold increase over the upper limit of the reference range in 25% of patients. Metabolite Cmax (133.3 ± 102.0 ng/ml) was elevated in 75% of patients, with a three to sevenfold increase over the upper limit of the reference range in 40% of patients. Patients with heart failure and LVADs are at increased risk of concentrated-related sildenafil adverse events.
No takes yet. Share an insight, caveat, or question.
Sabato et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: